The inclusion of RAS variants into BRAF and TERT variant assays reached a sensitivity of 70.5% (95% CI, 65.4%-75.2%) and a specificity of 88.8% (95% CI, 79.8%-94.1%), with a PPV of 96.1% (95% CI, 92.7%-98.0%) and an NPV of 43.4% (95% CI, 36.2%-50.9%) in distinguishing malignant neoplasms from benign and NIFTP tumors. This evidence concerns the gene TERT and cancer.